Facebook-f Linkedin Twitter

CONFERENCE COVERAGE: American Association for Cancer Research (AACR) Annual Meeting 2023

  1. Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma
  2. Amgen To Present Long-Term Outcomes For Lumakras® (Sotorasib) in KRAS G12C-Mutated NSCLC
  3. AstraZeneca advances its pipeline and highlights progress in immuno-oncology, ADCs, cell therapy and epigenetics
  4. BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors
  5. Imfinzi-based treatment before & after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable NSCLC in the AEGEAN Phase III trial
  6. Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre® (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma
  7. Innovent Announces Updated Data of Phase 1 Clinical Trial for IBI351 (KRASG12C Inhibitor) as Monotherapy for Solid Tumors
  8. Innovent Releases Final Analysis Results of ORIENT-16: the Phase 3 Study of Sintilimab in Combination with Chemotherapy for 1L Treatment of Gastric Cancer
  9. Kintara Therapeutics Announces Data Presentation of new solid tumor cancer therapies
  10. Lilly Announces Details of Presentations
  11. Merck’s KEYTRUDA + chemo Significantly Improved OS Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer
  12. Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma
  13. Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)
  14. MorphoSys & Incyte Announce Five-Year Results Of L-MIND Study Showed Durable Responses In R/R DLBCL Patients Treated With Monjuvi® (Tafasitamab-Cxix)
  15. Neoadjuvant Opdivo with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable NSCLC in Phase 3 CheckMate -816 Trial
  16. New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors
  17. Novel Allogeneic CAR T Cell Therapy Delivers Promising Early Results In Patients With Metastatic Clear Cell Renal Cell Carcinoma
  18. Novartis Announces Early Clinical Data For Unique KRASG12C Inhibitor
  19. RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study
  20. Roche’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
  21. Seagen to Present New Clinical Data From Broad Portfolio of Targeted Cancer Therapeutics
  22. Strata Oncology Announces Four Abstracts Accepted for Presentation
  23. Three Year Follow-Up Data from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) Confirm Prolonged PFS in 1L ALK-Positive Advanced Lung Cancer
  24. Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors

Stay up-to-date with our biotech and Onco News

Facebook Linkedin Twitter

MedNess Plus

About Us

Disclaimer: The editors take care to share authentic information. In case of any discrepancies please write to newsletter @ medness.org
The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of MedNess. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for MedNess. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. MedNess is a part of STEMPeers® which is a 501(c)(3) organization registered in PA as PhD Career Support Group. The organization helps create a growing network of STEM scientists that is involved in peer to peer mentoring and support.

Facebook Linkedin Twitter

Onco-This-Week

MedNess Plus

About Us

Disclaimer: The editors take care to share authentic information. In case of any discrepancies please write to newsletter @ medness.org
The sponsors do not have any influence on the nature or kind of the news/analysis reported in MedNess. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of MedNess. Examples of analysis performed within this article are only examples. They should not be utilized in real-world analytic products as they are based only on very limited and dated open source information. Assumptions made within the analysis are not reflective of the position of anyone volunteering or working for MedNess. This blog is strictly for news and information. It does not provide medical advice, diagnosis or treatment nor investment suggestions. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. MedNess is a part of STEMPeers® which is a 501(c)(3) organization registered in PA as PhD Career Support Group. The organization helps create a growing network of STEM scientists that is involved in peer to peer mentoring and support.